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Background: Some cardioactive vasodilating agents inhibit ventricular tachyarrhythmias (VT) associated
with acquired long QT syndrome (LQT). We tested whether a vasodilator without direct cardiac effect can
eliminate abnormal repolarization-related VT.
Methods: The effect of hydralazine on the occurrence of VT was assessed in a methoxamine-sensitized rabbit
model of acquired LQT. To verify that VTs in this animal model are triggered by early afterdepolarization
(EAD), monophasic action potential (MAP) on the left ventricular surface was recorded in open-chest rabbits.
Results: In control rabbits, combined administration of methoxamine and nifekalant frequently induced VTs
(16/20, 80%). In contrast, VT occurred only in 2 out of 14 rabbits treated with hydralazine (14.3%, Po0.0001
vs. control). After the treatment, blood pressure was lower in the hydralazine group than in the control group
(systolic pressure, 146719 vs. 165716 mmHg, Po0.0001; diastolic pressure, 54710 vs. 101711 mmHg,
Po0.0001). EAD-like hump was less frequently detected in hydralazine-treated rabbits (2/10) than in saline-
treated rabbits (9/10, Po0.005). Presence of a hump was signiﬁcantly related to the appearance of VTs
(Po0.05).
Conclusion: Hydralazine inhibited VT in a rabbit LQT model. Vasodilation may have a therapeutic effect on
abnormal repolarization-related VT.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Abnormal repolarization facilitates the advent of ventricular
tachyarrhythmias (VT). Bradycardia, ischemia, hypokalemia, and
some cardiotoxic drugs increase the cardiac vulnerability to
abnormal repolarization-related VT. Vasodilating agents such as
carperitide [1] and clonidine [2] inhibit VT in an experimental
model of acquired long QT syndrome (LQT). However, most
vasodilating agents concomitantly have a certain cardioactive
effect to some extent. In an earlier study, physiologically concei-
vable ﬂuctuation of volume load did not markedly inﬂuence the
electrophysiological properties or arrhythmogenicity of the canine
ventricle [3]. Thus, it still seems disputable if vasodilation can have
an appreciable impact on VT associated with acquired LQT.
In the present study, we tested whether hydralazine, a “direct
acting vasodilator” with little action on the myocardium, could
decrease the incidence of VT in an established rabbit LQT model but
with attenuated arrhythmogenic potential. The goal of this study was
to validate the view that vasodilatation itself has a therapeutic
implication for acquired LQT-related VT.t Rhythm Society. Published by Els
tsui, MD).2. Methods
2.1. Animal preparation
This experiment was approved by the local institutional review
board on November 1, 2007 (approval number: 07-012). All
procedures were carried out in accordance with the guidelines
by the Committee of Animal Care and Experiments of Teikyo
University.
Fifty-eight Japanese white rabbits (2.4–2.7 kg) were anesthe-
tized with intravenous isozol (62.5 mg/body). Additional doses
were given if necessary to maintain an appropriate level of
anesthesia. Rabbits were ventilated with room air through an
artiﬁcial respirator (model 6025, Ugo, Basile, Italy) via a tracheal
cannula. Arterial blood pressure was monitored using a right
femoral artery cannula attached to a Statham pressure transducer
(Ampliﬁer AP621G, Nihon Koden, Tokyo, Japan). Body temperature
was maintained at about 37 1C with an electrical blanket. Arterial
blood gases and electrolytes were measured with a portable
clinical analyzer (i-STAT 200A, i-STAT Corporation, Princeton, NJ,
USA). Tidal volume and respiratory rate were adjusted to maintain
arterial blood gases and pH within physiological ranges. Two
surface electrocardiograms, lead I and II, were continuously
monitored, and the data were stored in a personal computerevier B.V. All rights reserved.
Fig. 1. Experimental protocols for each group. In all rabbits, methoxamine and
nifekalant were given to induce ventricular tachyarrhythmias (VTs). After a 10-min
stabilization period, treatment using saline or hydralazine was started simulta-
neously with the administration of nifekalant until VT or until 20 min elapsed.
Fig. 2. Comparison of the incidence of ventricular tachyarrhythmia (VT). In control
rabbits treated with saline, VT was almost consistently induced by the adminis-
tration of methoxamine and nifekalant. Hydralazine reduced the incidence of VT.
K. Tsutsui et al. / Journal of Arrhythmia 30 (2014) 157–160158together with that for arterial blood pressure for subsequent
analysis (PowerLab 8-channel System, ADInstruments Pty Ltd,
Sydney, NSW, Australia).
2.2. Experimental protocol
2.2.1. Study 1: effect of hydralazine on VT in closed-chest rabbits
(n¼34)
Referring to an in vivo animal model of torsade de pointes
established by Carlsson et al. [4], we used 0.2 mg/kg/min of nifekalant
chloride concomitantly with methoxamine, an α-1 stimulant, at a rate
of 70 nmol/kg/min. This combination of the agents almost consistently
induced VT in the baseline state, namely, in 14 out of 15 rabbits.
VT developed in 10 out of 15 rabbits treated with hydralazine [1]. Thus,
hydralazine did not fully eliminate VT. Taking these observations into
consideration, we assumed that attenuation of arrhythmogenic poten-
tial of the model might be essential to detect the antiarrhythmic effect
of hydralazine. Consequently, we adopted slower infusion rate of
methoxamine.
The protocol of this part is schematically shown in Fig. 1. After a
10-min period of stabilization, methoxamine was intravenously
administered at 20 nmol/kg/min. A 10-min infusion of methoxamine
was followed by nifekalant chloride (0.2 mg/kg/min). Then, intrave-
nous infusion of either hydralazine at 2 mg/kg/min or 0.5 mL/min of
saline solution (control group) was introduced simultaneously with
the administration of nifekalant. Fourteen rabbits were assigned to
the hydralazine group. As a control, 20 rabbits were given 0.5 mL/min
of saline solution. We compared the incidence of VT between the
2 groups. Systolic and diastolic blood pressure (SBP and DBP), heart
rate (HR), number of premature ventricular contractions (PVCs) and
QTc intervals were recorded. For the rabbits that developed VT, time
to VT was measured.
2.2.2. Study 2: recording of monophasic action potential (MAP) in
open-chest rabbits (n¼20)
This part was performed to assess whether ventricular arrhythmias
in this model were actually caused by early afterdepolarization (EAD).
MAP was recorded in 20 open-chest rabbits. The heart was
exposed through a midsternal incision and suspended in a
pericardial cradle. MAP was recorded on the left ventricular
surface using a contact electrode with an interelectrode distance
of 3 mm. MAP signals were ampliﬁed with a frequency range of
0.1–10 kHz (AP-621G; Nihon Kohden, Tokyo, Japan), and were
performed in the baseline state and during treatment with
hydralazine (n¼10) or saline (n¼10) at the same dose as in Study 1.
MAP was accepted when the amplitude was stable and 410mV.
2.3. Deﬁnition and measurement
VT was deﬁned as an episode of at least 6 coupled ventricular
complexes. Heart rates and QT intervals were obtained from the
measurements of 3 consecutive RR intervals or those of 3 beats ineither lead with more prominent T waves, respectively. The QT
interval was corrected using the Bazett formula (QTc). The mea-
surements of variables in the baseline state were made prior to the
administration of methoxamine. Measurements during the treat-
ment with each agent were performed 5 min from the onset of
administration of nifekalant.
Frequent premature beats was deﬁned as more than 10 PVCs
occurring in a minute.2.4. Statistical analysis
All continuous data are expressed as mean7SD. Comparisons
of variables among the groups were performed using 2-way
analysis of variance. In the presence of a signiﬁcant P value,
further comparison between each pair of variables was performed
using the Bonferroni method. Intergroup difference in the inci-
dence of VT in Study 1 and the association between EAD-like
hump and the appearance of VT in Study 2 were tested using
Fisher's exact test. Probability values o0.05 were considered to
indicate signiﬁcance.3. Results
3.1. Part 1: incidence of VT in rabbits with or without hydralazine,
changes in hemodynamic and electrocardiographic variables, and
time to develop VT
VT appeared in 16 out of 20 control rabbits. In rabbits treated
with hydralazine, incidence of VT was signiﬁcantly lower than that
in the control group (2/14, Po0.0001, Fig. 2).
Hemodynamic parameters and QTc before and after the treat-
ment are shown in Table 1. SBP, DBP, and HR in the 2 groups were
similar at baseline. QTc intervals during saline infusion were not
consistently available because of frequent PVCs and VTs. After the
treatment, SBP was elevated and HR slowed down in all rabbits,
whereas DBP in the control group was not altered; hydralazine
even decreased DBP after the treatment. Compared with saline,
hydralazine was associated with less conspicuous changes
(Po0.0001 for both SBP and HR). Among the rabbits that devel-
oped VT, time to VT in the control group was longer than that in
the hydralazine group (10.975.7, n¼12 vs. 7.373.3, n¼4,
Po0.05).
Hydralazine was associated with lower incidence of frequent
premature beats (2/14 vs. 14/20, Po0.005) as compared with that
of the control group.
Fig. 3. (A) and (B) Illustrative electrocardiograms (ECGs) and epicardial mono-
phasic action potential (MAP). (A) In the saline group, early afterdepolarization
(EAD)-like humps, as indicated by arrows, were observed on MAP recordings
during the administration of methoxamine and nifekalant. Then a ventricular
ectopic beat triggered ventricular tachyarrhythmia (VT). (B) In contrast, both EAD-
like humps and VTs were abolished in most of the hydralazine-treated rabbits.
Table 2
Incidence of EAD-like humps in MAP recordings and VT.
Hump(+)/VT
(+)
Hump(+)/VT
(−)
Hump(−)/VT
(+)
Hump(−)/VT
(−)
Saline (n¼10) 9 0 0 1
Hydralazine
(n¼10)
0 2 2 6
Total no. 9 2 2 7
EAD¼early afterdepolarization, MAP¼monophasic action potential, and VT¼ven-
tricular tachyarrhythmia.
Table 1
Results in Study 1.
Treatment Control (n¼20) Hydralazine (n¼14) P value
VT 16/20 2/14 o 0.0001
SBP-Pre (mmHg) 133717 135719 n.s.
SBP-Post (mmHg) 165716 146719 o 0.0001
DBP-Pre (mmHg) 10079 9479 n.s.
DBP-Post (mmHg) 101711 54710 o 0.0001
HR-Pre (bpm) 292735 327749 n.s.
HR-Post (bpm) 221739 285755 o 0.0001
QTc-Pre 225756 240740 n.s.
QTc-Post N.A. 452780
All values except VT are presented as mean7SD.
VT¼ventricular tachyarrhythmia, SBP¼systolic blood pressure, DBP¼diastolic
blood pressure, HR¼heart rate, n.s.¼not signiﬁcant, and N.A.¼not available.
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Fig. 3A shows demonstrable electrocardiogram (ECG) and MAP
recordings from one of the control rabbits. Those of a rabbit
treated with hydralazine are shown in Fig. 3B. EAD-like hump
was less frequently detected in hydralazine-treated rabbits (2/10)than in saline-treated rabbits (9/10, Po0.005). Presence of a hump
was signiﬁcantly related to the advent of VTs (Po0.05, Table 2).4. Discussion
The major ﬁndings of the present study were as follows: (1)
hydralazine decreased the incidence of VT in a rabbit acquired LQT
model and (2) EAD-like hump was associated with the appearance
of VTs.
Because of its little cardiac effect, hydralazine is known as a
“direct vasodilator.” The main action of hydralazine is to inhibit the
IP3-induced release of Ca2+ from the sarcoplasmic reticulum in
vascular smooth muscle cells [5]. The present results demon-
strated that vasodilation has a therapeutic implication for abnor-
mal repolarization-related VT.
We observed that hydralazine decreased the incidence of EAD-
like hump in the MAP study, and that the vasodilator also
suppressed the frequency of PVCs. These ﬁndings indicated that
the anti-VT effect of hydralazine should be associated with
modiﬁcation in abnormal repolarization. Because the direct vaso-
dilator has minimal electrophysiological effect, this alteration is to
be derived from mechanical unloading and/or hemodynamic
reaction.
Mechanical stretch is one of the modulating factors of myo-
cardial electrophysiologic property, i.e., “mechano-electrical feed-
back,” and presumably its arrhythmogenicity. Ventricular loading
causes the following: (1) reduction of action potential duration
and refractoriness, (2) development of EAD, and (3) ectopic beats
originating from the afterdepolarization [6,7].
Calkins et al. demonstrated that volume loading has a greater
electrophysiological signiﬁcance under pathologic conditions such
as chronic infarction [8]. Some vasodilators can counteract such
electrophysiological changes and suppresses VT. Captopril pro-
longed the ventricular refractory period in patients with ventri-
cular dysfunction and inducible VT [9]. hANP and hydralazine
hampered VT in a cesium-induced rabbit model [10]. Our observa-
tion in the present study is in good agreement with this earlier
ﬁnding in that modiﬁcation of pressure and/or volume load
attenuates the ventricular arrhythmogenicity.
Prazosin (an alpha-1 blocker), clonidine (an alpha-2 agonist),
and hANP reduced VTs in a similar rabbit LQT model. Pinacidil, a
potassium channel opener, also decreased both arterial pressure
and the incidence of VT. All these pharmacological interventions
share direct cardiac effects. Therefore, their favorable effect on
abnormal repolarization-related VT may be attributable to direct
cardio-active action, and is not explained solely by indirect action
via attenuated pressure and/or volume load.
Hydralazine has a positive inotropic effect on isolated mam-
malian myocardium [11]. Additionally, it increases HR and cardiac
output, and enhances cardiac conduction in patients with cardio-
vascular diseases [11]. The cardiac effects are considered to be due
to resultant sympathetic drive to the heart, because beta blockers
abolished these phenomena [12]. Relatively higher HR during
K. Tsutsui et al. / Journal of Arrhythmia 30 (2014) 157–160160hydralazine infusion may be relevant to, if partly, its antiarrhyth-
mic action in this rabbit model because bradycardia is one of the
exacerbating factors of acquired LQT.
Patients with advanced heart failure, who naturally suffer from
continuous cardiac loading, are often confronted with life-
threatening VT. The use of a vasodilator is a primary choice for
the treatment of heart failure. The present study supports the view
that vasodilation itself is therapeutic for a certain type of VT.
Clinically, in some patients, volume and/or pressure load enhance
the risk of serious ventricular arrhythmias. If conventional antiar-
rhythmic treatment fails to decrease life-threatening VTs, reconsi-
deration of the hemodynamic condition may be desirable.5. Limitations
Spatial and temporal dispersion of repolarization are consid-
ered as determinants of initiation and maintenance of VT. We do
not know whether site-to-site heterogeneity of repolarization has
a relevance to VT in the model because MAP was recorded only
from a single epicardial surface.
Extrapolation of the ﬁnding in an animal LQT model to a
clinical setting is inevitably limited. Clinically, it is essential to
ameliorate triggering conditions of LQT such as hypokalemia and
bradycardia. It is not clear how the favorable effect of hydralazine
is related with autonomic and humoral changes.
Because the presence or absence of EAD-like hump was
subjectively judged, the result of Study 2 was not free from bias.
We do not deny that some other mechanism may have been
involved in the genesis of arrhythmias in the model.
The faster HR produced by hydralazine has a possible ther-
apeutic role in the VTs in this model. Bradycardia prolongs APD
and is known as one of the risk factors for Torsade de Pointes.
However, sustained sympathetic tone is not always therapeutic on
such VTs because it also deteriorates intracellular Ca2+ handling. In
the present study, hydralazine also suppressed EAD-like hump and
PVCs, suggesting that the vasodilation was supposed to produce
electrophysiological changes in the cardiomyocyte. Therefore,
accelerating HR is not the sole reason why hydralazine provided
an anti-VT effect. In other words, hydralazine may have additional
therapeutic effects beyond the resultant tachycardia.6. Conclusions
Hydralazine, which is considered to have minimal direct elec-
trophysiological inﬂuence on the ventricular myocardium, signiﬁ-
cantly inhibited VT. Although it is not clear how hemodynamicalterations produced by hydralazine affect the electrophysiological
properties of the myocardium, this result was consistent with
the view that vasodilation has a therapeutic effect on VT in
acquired LQT.7. Conﬂict of interest
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